Drug Research

Double Digit Growth Anticipated for Global Biopsy Device Market with revenues likely to reach US$ 2 Billion by 2022

March 21, 2018

Marketprognosis.com Publish a New Market Research Report On “Global Biopsy Device Market, Biopsy Procedure Volume, Company Product Analysis and Forecast To 2022” which contains global key player’s survey information and forecast to 2022. Overview of the Global Biopsy Device Market: The global market for Biopsy Device is anticipated to reach around US$ 2 Billion by […]

Cystic Fibrosis Therapeutics Market: Global Industry Insights and CAGR Analysis 2018 – 2024 with Major Key Vendors – Genentech, Novartis, Gilead Sciences, AbbVie, GlaxoSmithKline

March 21, 2018

Marketprognosis.com Publish a New Market Research Report On “Cystic Fibrosis Therapeutics Market Global Forecast to 2024” which contains global key player’s survey information and forecast to 2024. Overview of the Global Cystic Fibrosis Therapeutics Market: The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period. Cystic fibrosis […]

Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist

March 21, 2018

SAN DIEGO, March 21, 2018 /PRNewswire/ —   Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has been methodically optimizing small molecules that bind to, and activate, the NR2F6 nuclear receptor. The process is close to completion, with the primary and back up compounds being readied for final pre-clinical mouse experiments.   “We are currently […]

Envigo expands Livermore (USA) surgical facilities to meet rising demand from West Coast companies

March 21, 2018

East Millstone, NJ, USA, 21 March 2018: Envigo is investing in an expansion of its surgical facility at its Livermore, California site in response to large market demand from West Coast customers. The new expanded capabilities will help create a West Coast Centre of Excellence for surgical services and complement the company’s existing offering at […]

Elthera Announces Positive Preclinical Proof of Concept (POC) Studies and Start of New Financing Round

March 19, 2018

SCHLIEREN, Switzerland, March 19, 2018 /PRNewswire/ — Elthera is pleased to announce that it has demonstrated efficacy of its proprietary antibodies in tumor bearing animals. Dr. Anne Schmidt, Elthera CEO said, “We are very encouraged by these results demonstrating the efficacy of our antibodies in preclinical models of pancreatic and ovarian carcinomas, both areas where […]

Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile

March 19, 2018

TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a clinical stage biotechnology company, today announced the publication of a research paper entitled “Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection” in the peer reviewed journal, Frontiers in Microbiology, the largest microbiology journal in the world.   “Mutacin 1140 Lantibiotic Variants Are Efficacious […]

Autolus announces publication in Molecular Therapy on its small molecule-activated fast-acting permanent off switch

March 19, 2018

London, 19 March 2018 – Autolus Limited, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the publication of an article in Molecular Therapy describing its small molecule-activated off switch which is designed to allow for the selective elimination of T cells programmed to incorporate Caspase 9 (rapaCasp9) using rapamycin (sirolimus, Rapamune®). […]

Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018

March 16, 2018

EVANSTON, Ill., March 15, 2018 /PRNewswire/ — Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced the presentation of preclinical data that supports advancing the development of a novel N-methyl D-aspartate (NMDA) receptor modulator, NYX-458, as a treatment for cognitive impairment associated with Parkinson’s disease. Results from the preclinical […]

Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

March 15, 2018

VANCOUVER, March 14, 2018 /PRNewswire/ – Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that late-breaking preclinical results for its Chk1 inhibitor, SRA737, have been accepted for presentation in a poster at the […]

Study Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy Protocols

March 15, 2018

MENLO PARK, Calif., March 15, 2018 (GLOBE NEWSWIRE) — A new publication in the journal of the American Society of Gene & Cell Therapy demonstrates the utility of Single Molecule, Real-Time (SMRT®) Sequencing to assess the quality of viral vector preparations for clinical and basic research, with the ultimate goal of improving the safety and […]

Strata Oncology Announces New Partnerships with Aurora Health Care & UTHealth

March 14, 2018

Strata Precision Oncology Network™ now includes 10 healthcare systems providing no-cost tumor profiling and clinical trials system-wide ANN ARBOR, Mich., March 13, 2018 — Strata Oncology, a precision oncology company, today announced that Aurora Health Care, the largest healthcare system in Wisconsin, and University of Texas Health Sciences at Houston (UTHealth) have joined the Strata […]

Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program

March 13, 2018

GAITHERSBURG, Md., March 12, 2018 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced data from a pre-clinical study comparing SparVax-L and BioThrax® against anthrax infection. Data from the study showed a 67% survival rate in animals challenged with a lethal dose of anthrax after a single dose of SparVax-L, an anthrax […]

Biostage Preclinical Study Results Published in New Report

March 13, 2018

HOLLISTON, Mass., March 13, 2018 /PRNewswire/ — Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the publication of pre-clinical large-animal study results for its Cellspan™ esophageal implants. The study, published in Nature Scientific Reports, demonstrated the feasible and reproducible use of […]

AbCellera Awarded Multi-Year Contract to Lead the Development of a Rapid Response Platform Against Pandemic Viral Threats

March 13, 2018

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera Biologics Inc. announced today that it was awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to develop rapid countermeasures against viral outbreaks. Over the four-year contract, AbCellera will receive up to USD $30 million in funding to establish an end-to-end platform for rapid pandemic response, and will lead […]

Certara Launches Industry-First Quantitative Systems Pharmacology (QSP) Consortium on Immuno-oncology with Leading Pharma Company Members

March 13, 2018

Consortium will develop a QSP Immuno-oncology Simulator to test combination cancer therapies and different dose regimens and biomarkers in computer-generated, virtual patients     Certara®, the global leader in model-informed drug development and regulatory science, today announced the launch of its Quantitative Systems Pharmacology (QSP) Immuno-oncology Simulator Consortium.   QSP combines computational modeling and experimental […]

OncoSec Announces Publication In Nature Gene Therapy Demonstrating Efficacy Of IL-12 Intratumoral Gene Electrotransfer

March 12, 2018

SAN DIEGO, March 12, 2018 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that its manuscript, “Improving therapeutic efficacy of IL-12 intratumoral gene electrotransfer,” has been published in Nature Gene Therapy. The research, led by a team of OncoSec scientists, evolves the company’s current clinical EP platform to […]

Certara and Faculty from UNC Eshelman School of Pharmacy to Launch New Pharmacometrics Skills Competition at ASCPT 2018 Annual Meeting

March 12, 2018

Certara will co-chair the inaugural MIDD Gran Prix in addition to describing its latest PBPK and MBMA advances in 13 presentations and posters at the conference    Certara®, the global leader in model-informed drug development and regulatory science, today announced that it is partnering with faculty at the UNC Eshelman School of Pharmacy to launch […]

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies

March 6, 2018

TORONTO and CAMBRIDGE, MA, March 6, 2018 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer’s disease (AD), PMN310, showed similar ability to cross the blood brain barrier and penetrate the central nervous system (CNS) […]

ORYZON Announces Publication of Paper in Cancer Cell establishing the relevance of ORY-1001 as an antileukemic differentiating drug

March 6, 2018

MADRID, SPAIN and CAMBRIDGE, MA–(Marketwired – March 05, 2018) – Oryzon Genomics (ISIN Code: ES0167733015) (MAD: ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the publication by company scientists of a new paper in the March issue of Cancer Cell. The paper […]